Navigation Links
Einstein researcher receives American Cancer Society Medal of Honor
Date:11/9/2010

November 5, 2010 (BRONX, NY) Albert Einstein College of Medicine of Yeshiva University researcher Jeffrey Pollard, Ph.D., has received the prestigious Medal of Honor in Basic Science from the American Cancer Society (ACS) in recognition of his research into the critical role the tumor microenvironment plays in modulating cancer behavior, specifically the role that members of the innate immune cells called macrophages play both in normal development and in promoting tumor progression. These macrophages could hold the key to more targeted cancer treatments.

Insights into how normal body cells support tumor growth have led the way to a new wave of research and the development of therapeutics specifically targeting the support cells in the body that can aid in tumor development. Dr. Pollard's research has found that when macrophages are removed from the tumor microenvironment, the risk of cancer progressing to malignancy is reduced and its spread from the primary tumor site to distant sites lessens.

"I think that one of the major components of the therapeutic arsenal as we go forward will be to combine chemo-therapeutic drugs with drugs that target macrophages so that they can no longer support the tumor's ability to be malignant," said Dr. Pollard. "Further it gives another opportunity for therapy by using vaccination against tumor antigens combined with altering macrophages from tumor promoting to tumor rejecting. It gives us another prong in the attack on cancer."

Dr. Pollard is deputy director of the Albert Einstein Cancer Center, director of the Center for Study of Reproductive Biology and Women's Health and the Louis Goldstein Swan Chair in Women's Cancer Research at Einstein. He is also professor in the departments of developmental and molecular biology and obstetrics & gynecology and women's health at Einstein and Montefiore Medical Center.

This award from the American Cancer Society, the nation's leading voluntary health organization and largest non-governmental investor in cancer research, represents the Society's highest honor in recognition of outstanding contributions to fighting cancer.

The award was presented at the American Cancer Society's annual meeting in Atlanta, GA. In addition to Dr. Pollard, the ACS recognized Joseph Fraumeni, M.D., M.Sc., for Cancer Control, and Patricia Ganz, M.D., for Clinical Research.

This is the second ACS Medal of Honor awarded to a researcher at the Albert Einstein Cancer Center. Susan Band Horwitz, Ph.D., received the Medal of Honor in 2008 for Clinical Research.


'/>"/>

Contact: Kim Newman
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Related biology news :

1. Einstein receives $30 million to study protein form and function
2. Einstein designated an NIH Center of Excellence for aging research
3. Einstein receives $4 million to test HPV microbicide
4. Einstein researcher awarded prestigious cancer research grant
5. Einstein-Montefiore research tackles childhood obesity in the Bronx
6. Einstein researchers discover 2 new ways to kill TB
7. Einstein receives high-risk/high-reward cancer research funding
8. Einstein to develop anti-HIV drug delivery system
9. Einstein scientists move closer to a safer anthrax vaccine
10. Einstein researchers devise a fast and sensitive way to detect ricin
11. NIH funds research center for womens reproductive health at Einstein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2016)... , Dec 15, 2016 ... Research and Markets has announced the addition ... offering. The report forecasts the global military biometrics market ... The report has been prepared based on an in-depth market ... and its growth prospects over the coming years. The report also includes ...
(Date:12/15/2016)... , Dec. 14, 2016 "Increase in ... biometrics market" The mobile biometrics market is expected to ... 49.33 billion by 2022, at a CAGR of 29.3% ... factors such as the growing demand for smart devices, ... transactions. "Software component is expected to grow ...
(Date:12/8/2016)... 2016  Singulex, Inc., the leader in Next Generation ... a license and supply agreement with Thermo Fisher Scientific, ... Singulex access to Thermo Scientific BRAHMS PCT (Procalcitonin), a ... used to diagnose systemic bacterial infection and sepsis and ... aid in assessing the risk of critically ill patients ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... Whitehouse, NJ (PRWEB) , ... January 18, 2017 ... ... access to more and more E&L expertise. Within Albany Molecular Research, Inc. (AMRI), ... doubled in the past year and is planned for further growth in 2017. ...
(Date:1/18/2017)... ... 2017 , ... Researchers from a new study are stating that if levels of ... cancer treatment, this indicates there is still remaining prostate cancer cells that are more likely ... test has always been an indicator of whether a man’s prostate cancer is growing ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... the publishing of the latest paper by its Science Editor, Dr. Elisabeth Bik, ... Tijdschrift voor Medische Microbiologie). Dr. Bik joined uBiome in October 2016 from her ...
(Date:1/18/2017)...  HUYA Bioscience International, (HUYA), the leader in accelerating ... pharmaceutical innovations, announced today a strategic collaboration agreement with ... (referred to as CAS Innovation). The collaboration will focus ... scientists at CAS to meet the medical needs of ... first company to have recognized China,s ...
Breaking Biology Technology: